BEBT-507 / BeBetter Med - LARVOL DELTA

Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV) (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: BeBetter Med Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Polycythemia Vera

Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV) (clinicaltrials.gov) - P1 | N=90 | Not yet recruiting | Sponsor: BeBetter Med Inc

New P1 trial • Polycythemia Vera

The clinical trial application of BEBT-507, the first innovative siRNA drug of Bibet Pharmaceuticals, was accepted by CDE [Google translation] (bydrug.pharmcube.com) - "On September 13, 2024, the clinical trial application (IND) for the innovative small nucleic acid (siRNA) drug 'BEBT-507 Injection' for polycythemia vera independently developed by Guangzhou Bibet Pharmaceutical Co., Ltd. has been accepted by the Drug Review Center (CDE) of the National Medical Products Administration."

New trial • Hematological Malignancies • Oncology • Polycythemia Vera